Literature DB >> 8679126

Ribonucleoprotein complexes as autoantigens.

W J van Venrooij1, G J Pruijn.   

Abstract

Many intracellular proteins and nucleic acids, that are involved in important biosynthetic pathways, are targeted by autoantibodies occurring spontaneously in the sera of patients with systemic autoimmune diseases. Frequently, the autoantigens are assembled into multicomponent complexes containing both nucleic acid(s) and proteins. Recently, progress has been made in the study of autoantigenic ribonucleoprotein complexes, the most important of which are spliceosomal ribonucleoproteins, nucleolar ribonucleoproteins, Ro/La ribonucleoproteins and complexes of aminoacyl-tRNA synthetase and tRNA. In addition to new structural and functional information, important results have been obtained on epitope spreading, as well as on a potential role for apoptosis during the development of an autoimmune response against these complexes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8679126     DOI: 10.1016/0952-7915(95)80054-9

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  14 in total

1.  Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease.

Authors:  K Skriner; W H Sommergruber; V Tremmel; I Fischer; A Barta; J S Smolen; G Steiner
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Characterization of the autoantigen La (SS-B) as a dsRNA unwinding enzyme.

Authors:  P Hühn; G J Pruijn; W J van Venrooij; M Bachmann
Journal:  Nucleic Acids Res       Date:  1997-01-15       Impact factor: 16.971

3.  Herpes simplex virus type 1 2-kilobase latency-associated transcript intron associates with ribosomal proteins and splicing factors.

Authors:  M Ahmed; N W Fraser
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Antigen is required for maturation and activation of pathogenic anti-DNA antibodies and systemic inflammation.

Authors:  Jeganathan Venkatesh; Hajime Yoshifuji; Daisuke Kawabata; Prameladevi Chinnasamy; Anfisa Stanevsky; Christine M Grimaldi; Joel Cohen-Solal; Betty Diamond
Journal:  J Immunol       Date:  2011-03-28       Impact factor: 5.422

Review 5.  Advances in understanding the pathogenesis of primary Sjögren's syndrome.

Authors:  Gaëtane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2013-07-16       Impact factor: 20.543

6.  Molecular definition of heterogeneous nuclear ribonucleoprotein R (hnRNP R) using autoimmune antibody: immunological relationship with hnRNP P.

Authors:  W Hassfeld; E K Chan; D A Mathison; D Portman; G Dreyfuss; G Steiner; E M Tan
Journal:  Nucleic Acids Res       Date:  1998-01-15       Impact factor: 16.971

7.  RNA recognition motif (RRM) of La/SSB: the bridge for interparticle spreading of autoimmune response to U1-RNP.

Authors:  John G Routsias; Nikolaos Kyriakidis; Michael Latreille; Athanasios G Tzioufas
Journal:  Mol Med       Date:  2009-10-14       Impact factor: 6.354

8.  Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes.

Authors:  R Chauhan; R Handa; T P Das; U Pati
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

9.  Nuclear import and the evolution of a multifunctional RNA-binding protein.

Authors:  J S Rosenblum; L F Pemberton; N Bonifaci; G Blobel
Journal:  J Cell Biol       Date:  1998-11-16       Impact factor: 10.539

10.  Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease.

Authors:  Daniëlle Hof; Kalok Cheung; Dirk-Jan R A M de Rooij; Frank H van den Hoogen; Ger J M Pruijn; Walther J van Venrooij; Jos M H Raats
Journal:  Arthritis Res Ther       Date:  2005-01-11       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.